Skip to main content
Erschienen in: International Journal of Colorectal Disease 2/2011

01.02.2011 | Original Article

Neoadjuvant chemotherapy affects staging of colorectal liver metastasis—a comparison of PET, CT and intraoperative ultrasound

verfasst von: Johann Spatz, G. Holl, J. Sciuk, M. Anthuber, H. M. Arnholdt, B. Märkl

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Surgery for colorectal liver metastasis facilitates long-term survival, and neoadjuvant chemotherapy improves resectability but may also alter staging accuracy. The aim of this study was to evaluate the effects of neoadjuvant chemotherapy on the efficacy of positron emission tomography (PET), PET–computed tomography (CT), CT and intraoperative ultrasound (IUS) in the detection of liver metastasis.

Methods

Between January 2007 and January 2010, 34 patients with resectable colorectal liver metastasis were included in this retrospective analysis. Seventeen patients had received neoadjuvant chemotherapy. PET or PET–CT, CT or magnetic resonance imaging (MRI) and IUS were performed in all patients. Sensitivity, specificity, positive predictive value and negative predictive value were analysed. Histopathological examination of the resected specimens served as standard reference.

Results

A total of 109 liver segments were resected, of which 50 showed no metastatic involvement (45.9%). For patients without systemic chemotherapy, sensitivities for PET, CT/MRI and IUS were 92%, 64% and 100% respectively as compared with 63%, 65% and 94% for patients after neoadjuvant chemotherapy in a segment-based analysis. For PET, standardised uptake values were decreased by 3.9 in 10 patients after chemotherapy whereas lesion diameters were similar (3.0 vs. 3.2 cm). Additional metastases were detected by IUS in seven patients resulting in a change of operative procedure in 20.6%.

Conclusion

Staging accuracy of colorectal liver metastasis is influenced by neoadjuvant chemotherapy. For PET, decreased tumour metabolism rather than downsizing may account for a drop in sensitivity after neoadjuvant chemotherapy. IUS is critical to avoid incomplete resections.
Literatur
1.
Zurück zum Zitat Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures 2007. American Cancer Society, Atlanta Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global cancer facts & figures 2007. American Cancer Society, Atlanta
2.
Zurück zum Zitat Kune GA, Kune S, Field B, White R, Brough W, Schellenberger R, Watson LF (1990) Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne colorectal cancer study. Dis Colon Rectum 33(11):938–946CrossRefPubMed Kune GA, Kune S, Field B, White R, Brough W, Schellenberger R, Watson LF (1990) Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne colorectal cancer study. Dis Colon Rectum 33(11):938–946CrossRefPubMed
3.
Zurück zum Zitat Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ (1997) Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 84(12):1731–1736CrossRefPubMed Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ (1997) Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 84(12):1731–1736CrossRefPubMed
4.
Zurück zum Zitat Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410CrossRefPubMed Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410CrossRefPubMed
5.
Zurück zum Zitat Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23(33):8490–8499CrossRefPubMed Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23(33):8490–8499CrossRefPubMed
6.
Zurück zum Zitat Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4):644–657, discussion 657–648PubMed Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4):644–657, discussion 657–648PubMed
7.
Zurück zum Zitat Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249(3):420–425CrossRefPubMed Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249(3):420–425CrossRefPubMed
8.
Zurück zum Zitat Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580CrossRefPubMed Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580CrossRefPubMed
9.
Zurück zum Zitat Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36):9243–9249CrossRefPubMed Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36):9243–9249CrossRefPubMed
10.
Zurück zum Zitat Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M (2006) Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 93(8):1001–1006CrossRefPubMed Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M (2006) Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 93(8):1001–1006CrossRefPubMed
11.
Zurück zum Zitat Grundmann RT, Hermanek P, Merkel S, Germer CT, Grundmann RT, Hauss J, Henne-Bruns D, Herfarth K, Hermanek P, Hopt UT et al (2008) Diagnosis and treatment of colorectal liver metastases—workflow. Zentralbl Chir 133(3):267–284CrossRefPubMed Grundmann RT, Hermanek P, Merkel S, Germer CT, Grundmann RT, Hauss J, Henne-Bruns D, Herfarth K, Hermanek P, Hopt UT et al (2008) Diagnosis and treatment of colorectal liver metastases—workflow. Zentralbl Chir 133(3):267–284CrossRefPubMed
12.
Zurück zum Zitat Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13(1):58–65CrossRefPubMed Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13(1):58–65CrossRefPubMed
13.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016CrossRefPubMed Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016CrossRefPubMed
14.
Zurück zum Zitat Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M et al (2008) Update S3-guideline “colorectal cancer” 2008. Z Gastroenterol 46(8):799–840CrossRefPubMed Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M et al (2008) Update S3-guideline “colorectal cancer” 2008. Z Gastroenterol 46(8):799–840CrossRefPubMed
15.
Zurück zum Zitat Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985–992CrossRefPubMed Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20(6):985–992CrossRefPubMed
16.
Zurück zum Zitat Garcea G, Ong SL, Maddern GJ (2009) The current role of PET–CT in the characterization of hepatobiliary malignancies. HPB (Oxford) 11(1):4–17 Garcea G, Ong SL, Maddern GJ (2009) The current role of PET–CT in the characterization of hepatobiliary malignancies. HPB (Oxford) 11(1):4–17
17.
Zurück zum Zitat Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, Cunningham D, Cook GJ (2008) The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35(7):1323–1329CrossRefPubMed Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, Cunningham D, Cook GJ (2008) The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35(7):1323–1329CrossRefPubMed
18.
Zurück zum Zitat Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Krabbe PF, Oyen WJ (2009) Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 50(7):1036–1041CrossRefPubMed Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Krabbe PF, Oyen WJ (2009) Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 50(7):1036–1041CrossRefPubMed
19.
Zurück zum Zitat Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240(6):1027–1034, discussion 1035–1026CrossRefPubMed Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240(6):1027–1034, discussion 1035–1026CrossRefPubMed
20.
Zurück zum Zitat Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8):1311–1319CrossRefPubMed Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8):1311–1319CrossRefPubMed
21.
Zurück zum Zitat Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246(4):559–565CrossRefPubMed Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246(4):559–565CrossRefPubMed
22.
Zurück zum Zitat Coenegrachts K, De Geeter F, ter Beek L, Walgraeve N, Bipat S, Stoker J, Rigauts H (2009) Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 19(2):370–379CrossRefPubMed Coenegrachts K, De Geeter F, ter Beek L, Walgraeve N, Bipat S, Stoker J, Rigauts H (2009) Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 19(2):370–379CrossRefPubMed
23.
Zurück zum Zitat Konopke R, Bunk A, Kersting S (2008) Contrast-enhanced ultrasonography in patients with colorectal liver metastases after chemotherapy. Ultraschall Med 29(Suppl 4):S203–S209CrossRefPubMed Konopke R, Bunk A, Kersting S (2008) Contrast-enhanced ultrasonography in patients with colorectal liver metastases after chemotherapy. Ultraschall Med 29(Suppl 4):S203–S209CrossRefPubMed
24.
Zurück zum Zitat Wiering B, Vogel WV, Ruers TJ, Oyen WJ (2008) Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 25(6):413–420CrossRefPubMed Wiering B, Vogel WV, Ruers TJ, Oyen WJ (2008) Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig Surg 25(6):413–420CrossRefPubMed
25.
Zurück zum Zitat Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology 237(1):123–131CrossRefPubMed Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology 237(1):123–131CrossRefPubMed
26.
Zurück zum Zitat Larsen L, Rosenkilde M, Christensen H, Bang N, Bolvig L, Christiansen T, Laurberg S (2009) Can contrast-enhanced ultrasonography replace multidetector-computed tomography in the detection of liver metastasis from colorectal cancer? Eur J Radiol 69(2):308–313CrossRefPubMed Larsen L, Rosenkilde M, Christensen H, Bang N, Bolvig L, Christiansen T, Laurberg S (2009) Can contrast-enhanced ultrasonography replace multidetector-computed tomography in the detection of liver metastasis from colorectal cancer? Eur J Radiol 69(2):308–313CrossRefPubMed
27.
Zurück zum Zitat Rafaelsen SR, Jakobsen A, Danish Colorectal Cancer Group South UoSD (2010) Contrast enhanced ultrasonography versus multidetector-computed tomography in detection of liver metastases from colorectal cancer. A prospective, blinded, patient by patient analysis. Colorectal Dis. doi:10.1111/j.1463-1318.2010.02288.x Rafaelsen SR, Jakobsen A, Danish Colorectal Cancer Group South UoSD (2010) Contrast enhanced ultrasonography versus multidetector-computed tomography in detection of liver metastases from colorectal cancer. A prospective, blinded, patient by patient analysis. Colorectal Dis. doi:10.​1111/​j.​1463-1318.​2010.​02288.​x
28.
Zurück zum Zitat Castaing D, Emond J, Kunstlinger F, Bismuth H (1986) Utility of operative ultrasound in the surgical management of liver tumors. Ann Surg 204(5):600–605CrossRefPubMed Castaing D, Emond J, Kunstlinger F, Bismuth H (1986) Utility of operative ultrasound in the surgical management of liver tumors. Ann Surg 204(5):600–605CrossRefPubMed
29.
Zurück zum Zitat Sietses C, Meijerink MR, Meijer S, van den Tol MP (2010) The impact of intraoperative ultrasound on the surgical treatment of patients with colorectal liver metastasis. Surg Endosc 24(8):1917–1922CrossRef Sietses C, Meijerink MR, Meijer S, van den Tol MP (2010) The impact of intraoperative ultrasound on the surgical treatment of patients with colorectal liver metastasis. Surg Endosc 24(8):1917–1922CrossRef
30.
Zurück zum Zitat Wildi SM, Gubler C, Hany T, Petrowsky H, Clavien PA, Jochum W, Gerlach T, Fried M, Mullhaupt B (2008) Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET–CT. J Clin Ultrasound 36(1):20–26CrossRefPubMed Wildi SM, Gubler C, Hany T, Petrowsky H, Clavien PA, Jochum W, Gerlach T, Fried M, Mullhaupt B (2008) Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET–CT. J Clin Ultrasound 36(1):20–26CrossRefPubMed
31.
Zurück zum Zitat Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA (2006) Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 141(12):1220–1226, discussion 1227CrossRefPubMed Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA (2006) Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 141(12):1220–1226, discussion 1227CrossRefPubMed
32.
Zurück zum Zitat Adam R, Wicherts DA, de Haas RJ, Aloia T, Levi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26(10):1635–1641CrossRefPubMed Adam R, Wicherts DA, de Haas RJ, Aloia T, Levi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26(10):1635–1641CrossRefPubMed
33.
Zurück zum Zitat Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg AM, Siegel BA (2002) Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. Am J Roentgenol 178(2):353–358 Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg AM, Siegel BA (2002) Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. Am J Roentgenol 178(2):353–358
Metadaten
Titel
Neoadjuvant chemotherapy affects staging of colorectal liver metastasis—a comparison of PET, CT and intraoperative ultrasound
verfasst von
Johann Spatz
G. Holl
J. Sciuk
M. Anthuber
H. M. Arnholdt
B. Märkl
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 2/2011
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-010-1065-8

Weitere Artikel der Ausgabe 2/2011

International Journal of Colorectal Disease 2/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.